Successful Use of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with Lisocabtagene Maraleucel in a Renal Transplant Recipient with Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Authors

• Waqqas Tai, William Beaumont University Hospital
• Fatima Chaudhry, Macon & Joan Brock Virginia Health Sciences at Old Dominion UniversityFollow
• Nesreen Shahrour, Georgetown University School of Medicine
• Jessica Thomas, Corewell Health
• Afoma Anyadibe, Corewell Health William Beaumont University Hospital
• Anuoluwa Oyetoran, Corewell Health William Beaumont University Hospital
• Swathi Gopishetty, Corewell Health William Beaumont University Hospital
• Precious Idogun, Corewell Health
• Dilip Samarapungavan, Corewell Health William Beaumont University Hospital
• Jassim H. Sarmad, Corewell Health William Beaumont University Hospital
• Ishmael Jaiyesimi, Corewell Health William Beaumont University Hospital

ORCID

0009-0007-3966-6976 (Chaudhry)

Document Type

Article

Publication Date

2026

DOI

10.7759/cureus.103667

Publication Title

Cureus

Volume

18

Issue

2

Pages

e103667

Abstract

This case describes a 53-year-old male with end-stage renal disease who developed monomorphic post-transplant lymphoproliferative disorder (PTLD) in the form of diffuse large B-cell lymphoma (DLBCL) after kidney transplantation. Despite initial treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), the patient's disease progressed, and he was referred for chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel). Given his post-transplant status, his immunosuppressive agents (tacrolimus and mycophenolate) were held, and prednisone was tapered to 5 mg daily to maintain minimal baseline immunosuppression. After lymphodepleting chemotherapy and liso-cel infusion, the patient experienced no significant toxicities, including cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). This case underscores the potential of CAR-T therapy for refractory/relapsed DLBCL in post-transplant patients, emphasizing the need for careful immunosuppressive management to balance graft protection and treatment efficacy.

Rights

© Copyright 2026 Tai et al.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Original Publication Citation

Tai, W., Chaudhry, F., Shahrour, N., Thomas, J., Anyadibe, A., Oyetoran, A., Gopishetty, S., Idogun, P., Samarapungavan, D., Sarmad, J. H., & Jaiyesimi, I. (2026). Successful use of chimeric antigen receptor T-cell (CAR-T) therapy with lisocabtagene maraleucel in a renal transplant recipient with refractory/relapsed diffuse large B-cell lymphoma (DLBCL). Cureus, 18(2), Article e103667. https://doi.org/10.7759/cureus.103667

Repository Citation

Tai, W., Chaudhry, F., Shahrour, N., Thomas, J., Anyadibe, A., Oyetoran, A., Gopishetty, S., Idogun, P., Samarapungavan, D., Sarmad, J. H., & Jaiyesimi, I. (2026). Successful use of chimeric antigen receptor T-cell (CAR-T) therapy with lisocabtagene maraleucel in a renal transplant recipient with refractory/relapsed diffuse large B-cell lymphoma (DLBCL). Cureus, 18(2), Article e103667. https://doi.org/10.7759/cureus.103667